MA39957A - Vaccin néonatal - Google Patents

Vaccin néonatal

Info

Publication number
MA39957A
MA39957A MA039957A MA39957A MA39957A MA 39957 A MA39957 A MA 39957A MA 039957 A MA039957 A MA 039957A MA 39957 A MA39957 A MA 39957A MA 39957 A MA39957 A MA 39957A
Authority
MA
Morocco
Prior art keywords
peptides
nucleic acids
relates
women
neonatal vaccine
Prior art date
Application number
MA039957A
Other languages
English (en)
Other versions
MA39957B1 (fr
Inventor
Neves Ferreira Da Silva Paula Maria Das
Pedro Jorge Fonseca Madureira
Original Assignee
Univ Do Porto Reitoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP14398006.8A external-priority patent/EP2955194A1/fr
Application filed by Univ Do Porto Reitoria filed Critical Univ Do Porto Reitoria
Publication of MA39957A publication Critical patent/MA39957A/fr
Publication of MA39957B1 publication Critical patent/MA39957B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01022—Lactaldehyde dehydrogenase (1.2.1.22)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)

Abstract

Cette invention concerne des peptides dérivés d'une protéine ubiquitaire, et des acides nucléiques codant pour ces peptides. L'invention concerne également diverses utilisations de ces peptides et acides nucléiques, par exemple, à titre d'antigènes se prêtant à une utilisation dans des vaccins per se et dans la génération d'anticorps utilisables dans des médicaments thérapeutiques destinés à prévenir, améliorer ou traiter les infections provoquées par des bactéries induisant une septicémie. L'invention profite plus particulièrement aux hôtes immunodéprimés, tels que les nouveau-nés, les bébés, les enfants, les femmes d'âge fertile, les femmes enceintes, les fœtus, les personnes âgées et les diabétiques.
MA39957A 2014-06-12 2015-06-12 Vaccin néonatal MA39957B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14398006.8A EP2955194A1 (fr) 2014-06-12 2014-06-12 Vaccin néonatal
EP15398003 2015-03-30
PCT/EP2015/063243 WO2015189422A1 (fr) 2014-06-12 2015-06-12 Vaccin pour hôtes immunodéprimés

Publications (2)

Publication Number Publication Date
MA39957A true MA39957A (fr) 2017-04-19
MA39957B1 MA39957B1 (fr) 2021-04-30

Family

ID=53385660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39957A MA39957B1 (fr) 2014-06-12 2015-06-12 Vaccin néonatal

Country Status (17)

Country Link
US (3) US11066652B2 (fr)
EP (1) EP3155004B1 (fr)
JP (2) JP6813480B2 (fr)
KR (2) KR20170018920A (fr)
CN (1) CN106795502B (fr)
CA (1) CA2969878C (fr)
CY (1) CY1124388T1 (fr)
DK (1) DK3155004T3 (fr)
ES (1) ES2862534T3 (fr)
HR (1) HRP20210458T1 (fr)
HU (1) HUE053668T2 (fr)
LT (1) LT3155004T (fr)
MA (1) MA39957B1 (fr)
PL (1) PL3155004T3 (fr)
RS (1) RS61549B1 (fr)
SI (1) SI3155004T1 (fr)
WO (1) WO2015189422A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053668T2 (hu) 2014-06-12 2021-07-28 Univ Do Porto Reitoria Oltóanyag immunkompromittáltak számára
EP3565576A1 (fr) 2017-01-05 2019-11-13 Evaxion Biotech ApS Vaccins ciblantpseudomonas aeruginosa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055893A1 (fr) 1998-04-29 1999-11-04 University Of Southern California Vecteurs retroviraux incluant des proteines d'escorte a enveloppe modifiee
MX2007009512A (es) 2005-02-08 2008-02-21 New York Blood Ct Inc Neutralizacion de anticuerpos monoclonales contra coronavirus asociado con sindrome respiratorio agudo severo.
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
ES2298055A1 (es) 2006-08-09 2008-05-01 Fundacion Marques De Valdecilla Peptidos inmunogenicos frente a los generos listeria y mycobacterium, anticuerpos y usos de los mismos.
WO2010150242A2 (fr) * 2009-06-25 2010-12-29 Protea Vaccine Technologies Ltd. Peptides de streptococcus pneumoniae immunogènes et multimères peptidiques
EP2470010A4 (fr) 2009-08-26 2013-02-27 The Feinstein Inst Medical Res Procédés de traitement de conditions médiées par la cascade inflammatoire de cytokines au moyen d'inhibiteurs de gapdh
WO2011067758A2 (fr) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
EP2550529B1 (fr) * 2010-03-23 2021-11-17 Iogenetics, LLC. Procédés bioinformatiques pour déterminer la liaison de peptides
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
HUE053668T2 (hu) 2014-06-12 2021-07-28 Univ Do Porto Reitoria Oltóanyag immunkompromittáltak számára

Also Published As

Publication number Publication date
SI3155004T1 (sl) 2021-08-31
CN106795502B (zh) 2021-12-14
CY1124388T1 (el) 2022-07-22
CA2969878C (fr) 2021-05-04
MA39957B1 (fr) 2021-04-30
EP3155004A1 (fr) 2017-04-19
LT3155004T (lt) 2021-03-25
KR20200013809A (ko) 2020-02-07
US11066652B2 (en) 2021-07-20
HUE053668T2 (hu) 2021-07-28
WO2015189422A1 (fr) 2015-12-17
JP2021000134A (ja) 2021-01-07
DK3155004T3 (da) 2021-04-06
PL3155004T3 (pl) 2021-10-25
JP6813480B2 (ja) 2021-01-13
KR20170018920A (ko) 2017-02-20
US20240191209A1 (en) 2024-06-13
US20170191040A1 (en) 2017-07-06
ES2862534T3 (es) 2021-10-07
EP3155004B1 (fr) 2021-01-13
US20220049229A1 (en) 2022-02-17
US11834684B2 (en) 2023-12-05
HRP20210458T1 (hr) 2021-05-14
RS61549B1 (sr) 2021-04-29
CA2969878A1 (fr) 2015-12-17
JP2017518769A (ja) 2017-07-13
CN106795502A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
BR112015023105A2 (pt) construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a?
MA44059B1 (fr) Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112017015906A2 (pt) complexo compreendendo um peptídeo de penetração celular, uma carga e um agonista de peptídeo tlr
BR112017014209A2 (pt) design de aparelhos dentários auxiliado por sistema de computador
EA201792501A1 (ru) Вакцины для лечения и профилактики рака
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
BR112018073843A2 (pt) anticorpos de peptídeo beta amiloide anti-n3pglu e usos dos mesmos
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
EA201071365A1 (ru) Моноклональные антитела, имеющие гомоподтип кросс-нейтрализующих свойств против вируса гриппа а подтипа н1
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
EA201591579A1 (ru) Способы лечения болезни крона при помощи анти-il-23 антитела
EP4272750A3 (fr) Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
BR112014032682A2 (pt) anticorpo monoclonal humano contra a proteína vp1 do vírus jc
TR201911232T4 (tr) Otoimmünite gelişimine yönelik coriolus versicolorun ekstraktını içeren topikal bileşimler.
MX2020012913A (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
MA39957A (fr) Vaccin néonatal
MX2021010021A (es) Proteínas sintéticas autoensamblables.
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MX2019007924A (es) Vacunas contra la influenza.
EA201401352A1 (ru) Вакцина против вируса шмалленберга (sbv), способы ее получения и применения